Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects.

International journal of technology assessment in health care - 1 Jan 2008

Compagni Amelia, Bartoli Simona, Buehrlen Bernhard, Fattore Giovanni, Ibarreta Dolores, de Mesa Emma Gutierrez

Abstract excerpt

OBJECTIVES: The study aims at evaluating the economic evidence related to testing for genetic variants of the drug-metabolizing enzyme, TPMT. Detecting TPMT genetic variants before the administration of azathioprine (AZA) has the potential to prevent serious and costly adverse drug reactions (ADR...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azathioprine
Share to Biotransformation
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to TPMT gene

Share to Genetic Variation

Share to Methyltransferases

Share to Neutropenia

Share to Pharmacogenetics

Source

Identifiers

PMID: 18601797
DOI: 10.1017/S0266462308080392

Genes

TPMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-18601797-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Avoiding adverse drug reactions by pharmacogenetic testing: a systematic review of the economic evidence in the case of TPMT and AZA-induced side effects.PMID 18601797Read ↗

A Systematic Review of Economic Evaluations of Pharmacogenetic Testing for Prevention of Adverse Drug Reactions.Semantic proximity Read ↗

The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine.Semantic proximity Read ↗

Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.Semantic proximity Read ↗

Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines.Semantic proximity Read ↗

Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain.Semantic proximity Read ↗

Economic Evaluation of Pharmacogenetic Tests in Patients Subjected to Renal Transplantation: A Review of LiteratureSemantic proximity Read ↗

Pharmacoeconomic analyses of azathioprine, methotrexate and prospective pharmacogenetic testing for the management of inflammatory bowel disease.Semantic proximity Read ↗

Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.Semantic proximity Read ↗

Economic evaluations of pharmacogenetic and genomic screening programs: update of the literature.Semantic proximity Read ↗

A pragmatic randomized controlled trial of thiopurine methyltransferase genotyping prior to azathioprine treatment: the TARGET study.Semantic proximity Read ↗

Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications.Semantic proximity Read ↗

Cost‐Effectiveness of Panel Tests for Multiple Pharmacogenes Associated With Adverse Drug Reactions: An Evaluation FrameworkSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.